Home Page
Genentech, the first publicly owned biotechnology company, recently completed an individualized neoantigen-specific immunotherapy (iNeST) facility on its campus in Hillsboro, Oregon. Using proprietary algorithms, the iNeST process involves DNA extraction from an individual patient's tumor cells and sequences, according to the company.
(All Fields Required)
Site-wide Scheduled Maintenance for September 27, 2025 from 12 P.M. to 6 P.M. CDT. Expect intermittent web site availability during this time period.
×Contact Us
For More Info!
